GlassScriptPhysician profile
Kacey Breaux Phillips
NPI 1629712310
$2,558.36
in general payments reported to CMS, 2019-2025
26 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $256 · 2024: $773 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.95 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $437.44 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $275.63 | 2025 | Dupixent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.47 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $196.82 | 2024-2025 | Eliquis, Camzyos |
| Atricure, INC. | $194.66 | 2023-2025 | Synergy Ablation System |
| Astrazeneca Pharmaceuticals LP | $168.73 | 2022-2025 | Tezspire, Farxiga, Breztri |
| Galderma Laboratories, L.P. | $146.21 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $133.88 | 2022-2023 | Verquvo |
| Glaxosmithkline, LLC. | $105.86 | 2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $88.80 | 2025 | Andembry, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $79.27 | 2025 | Neffy |
| Boston Scientific Corporation | $68.11 | 2024-2025 | Emblem Mri S-Icd, Accolade Sr, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $64.14 | 2023-2024 | |
| Novo Nordisk INC | $62.46 | 2024 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $57.99 | 2023-2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.36 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.90 | 2022 | |
| Scpharmaceuticals INC. | $32.46 | 2024 | |
| Genzyme Corporation | $24.87 | 2025 | |
| Abbott Laboratories | $24.45 | 2025 | Cardiomems |
| Paratek Pharmaceuticals, INC. | $21.65 | 2025 | Xhance |
| Verona Pharma, INC. | $21.45 | 2025 | Ohtuvayre |
| Alnylam Pharmaceuticals INC. | $20.29 | 2025 | Amvuttra |
| Genentech USA, INC. | $19.79 | 2025 | Xolair |
| Azurity Pharmaceuticals, INC. | $14.37 | 2025 | Alvesco |
| Medtronic, INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.